Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRO95780 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PRO95780 | DRUG | Intravenous repeating dose |
| rituximab | DRUG | Intravenous repeating dose |
Inclusion Criteria: * Signed Informed Consent Form * Age ≥ 18 years * Diagnosis of follicular, CD20-positive B-cell NHL * Progression of disease after an objective response or stable disease lasting \> 6 months following completion of the most recent rituximab-containing regimen * Measurable diseas...
PRO95780 is an investigational small molecule being studied for the treatment of Non-Hodgkin's Lymphoma. It was evaluated specifically in patients whose disease had progressed following prior rituximab therapy, and it was tested in combination with rituximab in that setting.
PRO95780 is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche sponsored the clinical program evaluating the drug in Non-Hodgkin's Lymphoma, including the Phase 2 study that combined it with rituximab in patients previously treated with rituximab.
PRO95780 is in Phase 2 development. It is an investigational agent and has not been approved by the FDA. The Phase 2 program in Non-Hodgkin's Lymphoma has been completed, and no trials of PRO95780 are currently listed as active.
PRO95780 has been studied in one clinical trial, NCT00517049, titled A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy. That Phase 2 trial enrolled 49 patients, was uncontrolled, and has been completed.
No. PRO95780 is an investigational drug and has not been approved by the FDA. It remains in clinical development at the Phase 2 stage, with its single completed trial in Non-Hodgkin's Lymphoma evaluating the combination of PRO95780 and rituximab in patients whose disease progressed after prior rituximab therapy.